Holen Sie sich die Stockscreener-App
7.37
0.41%
0.03
Schlusskurs vom Vortag:
$7.34
Offen:
$7.4
24-Stunden-Volumen:
342.53K
Relative Volume:
0.77
Marktkapitalisierung:
$493.00M
Einnahmen:
$555.06M
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-12.28
EPS:
-0.6
Netto-Cashflow:
$29.05M
1W Leistung:
+6.50%
1M Leistung:
+11.67%
6M Leistung:
-29.20%
1J Leistung:
-10.99%
1-Tages-Spanne:
$7.23
$7.42
1-Wochen-Bereich:
$6.76
$7.58
52-Wochen-Spanne:
$5.81
$14.38
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Vergleichen Sie BVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.37 | 490.99M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
What moving averages say about Bioventus Inc.Quarterly Profit Review & Community Driven Trade Alerts - Newser
Advanced analytics toolkit walkthrough for Bioventus Inc.Earnings Miss & Weekly High Conviction Trade Ideas - Newser
Is Bioventus Inc. Forming a Bottom PatternJuly 2025 Final Week & Smart Investment Allocation Insights - newsyoung.net
Tick level data insight on Bioventus Inc. volatilityEarnings Performance Report & Daily Oversold Stock Bounce Ideas - Newser
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative - simplywall.st
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT - MSN
Shareholders Can Be Confident That Bioventus' (NASDAQ:BVS) Earnings Are High Quality - ca.finance.yahoo.com
Is Bioventus (NASDAQ:BVS) A Risky Investment? - 富途牛牛
What makes Bioventus Inc. stock price move sharplyRapid Return Stock Portfolio - newsyoung.net
Bioventus (NASDAQ:BVS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Bioventus Inc.’s Price Action Aligns with Quant Signals [July 2025 Technicals]Free Growth-Oriented Investment Plans - sundaytimes.kr
12 Best Medical Device Stocks to Buy According to Analysts - Insider Monkey
Bioventus at Canaccord Conference: Strategic Growth Path By Investing.com - Investing.com Australia
Bioventus at Canaccord Conference: Strategic Growth Path - Investing.com
Cantor Fitzgerald Reaffirms Their Buy Rating on Bioventus (BVS) - The Globe and Mail
Bioventus to Present at Canaccord Genuity Global Growth Conference on August 12, 2025. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Bioventus stock By Investing.com - Investing.com Nigeria
Bioventus Inc. Crosses 200 Day MA — Signal or NoiseTarget Return Focused Trade Insights Shared - metal.it
Bioventus Earnings Call: Strong Growth and Resilience - TipRanks
Should Investors Capitalize on Bioventus' Earnings Outperformance Amid Industry Lags? - AInvest
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Bioventus Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Bioventus Inc. (NASDAQ:BVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance - MSN
Bioventus Q2 Earnings Call: Robust Growth and Strategic Resilience - AInvest
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - The Manila Times
Exclusive: Bioventus CEO Reveals Future Growth Plans at Major Healthcare Conference - Stock Titan
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $15 - 富途牛牛
Bioventus Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Bioventus Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) - Seeking Alpha
Bioventus Inc. Reports Q2 2025 Financial Results - TipRanks
Bioventus Q2 2025: Key Contradictions Unveiled on Tariffs, Growth Projections, and Market Dynamics - AInvest
Bioventus Q2 2025 slides: 6% organic growth despite revenue dip, FDA clearance boosts outlook By Investing.com - Investing.com South Africa
Bioventus Q2 2025 slides: 6% organic growth despite revenue dip, FDA clearance boosts outlook - Investing.com
Bioventus: Q2 Earnings Snapshot - The Washington Post
Transcript : Bioventus Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Earnings call transcript: Bioventus Q2 2025 sees steady EPS, revenue beat - Investing.com Canada
Earnings call transcript: Bioventus Q2 2025 sees steady EPS, revenue beat By Investing.com - Investing.com South Africa
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - sharewise.com
Bioventus Inc. Provides Earnings Guidance for the Year 2025 - MarketScreener
Bioventus Inc Q2 2025 Earnings: Revenue Beats at $147.7M, EPS Mi - GuruFocus
Bioventus reports Q2 EPS 21c, consensus 20c - TipRanks
Bioventus Inc. SEC 10-Q Report - TradingView
Bioventus Q2 2025 swings to $0.11 EPS, trims debt with new 2030 loan | KAR SEC FilingForm 8-K - Stock Titan
Bioventus Reports Second Quarter Financial Results - TradingView
Bioventus earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Bioventus Q2 revenue dips 2.4%, organic growth 6.2% - MarketScreener
Bioventus Reports Second Quarter Financial Results | BVS Stock N - GuruFocus
Bioventus Q2 revenue down 2.4% YoY, EPS up 31%, cash ops up 71%. - AInvest
What To Expect From Bioventus Inc (BVS) Q2 2025 Earnings - GuruFocus
Bioventus enters into a new $400M credit agreement, lowering interest expenses - MSN
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioventus Inc-Aktie (BVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bartholdson John A. | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
72,045 |
| SUTTER MARTIN P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| STALNECKER SUSAN M | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
105,957 |
| NOHRA GUY P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
126,610 |
| NEELS GUIDO J | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| McMurry-Heath Michelle | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
74,698 |
| Ladone Mary Kay | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
78,981 |
| HAWKINS WILLIAM A | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
257,851 |
| Beyer Pat | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
76,436 |
| Singleton Mark Leonard | SVP & CFO |
Apr 11 '25 |
Sale |
7.57 |
3,875 |
29,334 |
141,088 |
1.74%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):